Novel mGluR5 Positive Allosteric Modulator Improves Functional Recovery, Attenuates Neurodegeneration, and Alters Microglial Polarization after Experimental Traumatic Brain Injury

Neurotherapeutics

Volumn 11, Issue 4, 2014, Pages 857-869

  Loane, David J ^a   Stoica, Bogdan A ^a   Tchantchou, Flaubert ^a   Kumar, Alok ^a   Barrett, James P ^a   Akintola, Titilola ^a   Xue, Fengtian ^b   Conn, P Jeffrey ^c   Faden, Alan I ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Functional recovery; Metabotropic glutamate receptor 5; Microglial activation; Neuroprotection; Positive allosteric modulator; Traumatic brain injury

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; CHLORDANE; METABOTROPIC RECEPTOR 5; NEUROPROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG; VU 0360172; 2-CHLORO-5-HYDROXYPHENYLGLYCINE; 3-((2-METHYL-1,3-THIAZOL-4-YL)ETHYNYL)PYRIDINE; CYBB PROTEIN, MOUSE; GLYCINE; GRM5 PROTEIN, MOUSE; INDUCIBLE NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; NOS2 PROTEIN, MOUSE; PHENYLACETIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; HIPPOCAMPUS; MALE; MICROGLIA; MICROGLIAL CELL CULTURE; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TRAUMATIC BRAIN INJURY; AGONISTS; ALLOSTERISM; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; BRAIN INJURIES; C57BL MOUSE; CELL COUNT; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY;

ALLOSTERIC REGULATION; ANIMALS; BRAIN INJURIES; CELL COUNT; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GLYCINE; HIPPOCAMPUS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; NADPH OXIDASE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; PHENYLACETATES; PYRIDINES; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECOVERY OF FUNCTION; THIAZOLES;

EID: 84919863194     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0298-6     Document Type: Article

References (46)

1. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41–54. doi:10.1038/nrd2760.
2. Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 2014;61:55–71. doi:10.1016/j.nbd.2013.09.013.
3. Nicoletti F, Bockaert J, Collingridge GL, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011;60:1017–1041. doi:10.1016/j.neuropharm.2010.10.022.
4. Byrnes KR, Loane DJ, Faden AI. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics. 2009;6:94–107. doi:10.1016/j.nurt.2008.10.038.
5. Allen JW, Knoblach SM, Faden AI. Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Differ 2000;7:470–476. doi:10.1038/sj.cdd.4400678.
6. Allen JW, Eldadah BA, Faden AI. Beta-amyloid-induced apoptosis of cerebellar granule cells and cortical neurons: exacerbation by selective inhibition of group I metabotropic glutamate receptors. Neuropharmacology 1999;38:1243–1252.
7. Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL. Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury. J Clin Neurosci 2006;13:1023–1027.
8. Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W. Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol 2007;554:18–29.
9. Movsesyan VA, Stoica BA, Faden AI. MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem 2004;89:1528–1536.
10. Vincent AM, TenBroeke M, Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Exp Neurol 1999;155:79–94. doi:10.1006/exnr.1998.6966.
11. Zhu P, DeCoster MA, Bazan NG. Interplay among platelet-activating factor, oxidative stress, and group I metabotropic glutamate receptors modulates neuronal survival. J Neurosci Res 2004;77:525–531. doi:10.1002/jnr.20175.
12. Bao WL, Williams AJ, Faden AI, Tortella FC. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res 2001;922:173–179.
13. Byrnes KR, Loane DJ, Stoica BA, Zhang J, Faden AI. Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury. J Neuroinflammation. 2012;9:43. doi:10.1186/1742-2094-9-43.
14. Byrnes KR, Stoica B, Riccio A, Pajoohesh-Ganji A, Loane DJ, Faden AI. Activation of metabotropic glutamate receptor 5 improves recovery after spinal cord injury in rodents. Ann Neurol 2009;66:63–74. doi:10.1002/ana.21673.
15. Chen T, Zhang L, Qu Y, Huo K, Jiang X, Fei Z. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med 2012;29:630–636. doi:10.3892/ijmm.2011.870.
16. Loane DJ, Stoica BA, Byrnes KR, Jeong W, Faden AI. Activation of mGluR5 and inhibition of NADPH oxidase improves functional recovery after traumatic brain injury. J Neurotrauma 2013;30:403–412. doi:10.1089/neu.2012.2589.
17. Wang JW, Wang HD, Cong ZX, Zhang XS, Zhou XM, Zhang DD. Activation of metabotropic glutamate receptor 5 reduces the secondary brain injury after traumatic brain injury in rats. Biochem Biophys Res Commun 2013;430:1016–1021. doi:10.1016/j.bbrc.2012.12.046.
18. Loane DJ, Stoica BA, Faden AI. Metabotropic glutamate receptor-mediated signaling in neuroglia. Wiley Interdiscip Rev Membr Transp Signal 2012;1:136–150. doi:10.1002/wmts.30.
19. Byrnes KR, Stoica B, Loane DJ, Riccio A, Davis MI, Faden AI. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 2009;57:550–560. doi:10.1002/glia.20783.
20. Loane DJ, Stoica BA, Pajoohesh-Ganji A, Byrnes KR, Faden AI. Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J Biol Chem 2009;284:15629-39. doi:10.1074/jbc.M806139200.
21. Loane DJ, Kumar A, Stoica BA, Cabatbat R, Faden AI. Progressive neurodegeneration after experimental brain trauma: association with chronic microglial activation. J Neuropathol Exp Neurol 2014;73:14–29. doi:10.1097/NEN.0000000000000021.
22. Homayoun H, Moghaddam B. Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur J Pharmacol 2010;639:33–39. doi:10.1016/j.ejphar.2009.12.042.
23. Kinney GG, Burno M, Campbell UC, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 2003;306:116–123. doi: 10.1124/jpet.103.048702.
24. Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutarnate 5 (rnGlu5) receptors reverses N-methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007;62:739–746. doi: 10.1016/j.biopsych.2006.12.003.
25. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004;29:1259–1269. doi: 10.1038/sj.npp.1300417.
26. Kinney GG, O'Brien JA, Lemaire W, et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005;313:199–206. doi: 10.1124/jpet.104.079244.
27. Gravius A, Dekundy A, Nagel J, More L, Pietraszek M, Danysz W. Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm 2008;115:1609–1619. doi: 10.1007/s00702-008-0098-4.
28. Gass JT, Olive MF. Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol Psychiatry 2009;65:717–20. doi: 10.1016/j.biopsych.2008.11.001.
29. Olive MF. Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. Eur J Pharmacol 2010;639:47–58. doi:10.1016/j.ejphar.2010.01.029.
30. Ayala JE, Chen YL, Banko JL, et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009;34:2057–2071. doi: 10.1038/Npp.2009.30.
31. Xue F, Stoica BA, Hanscom M, Kabadi SV, Faden AI. Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGluR5) attenuate microglial activation. CNS Neurol Disord Drug Targets 2013;13:558–566
32. Rodriguez AL, Grier MD, Jones CK, et al. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 2010;78:1105–1123. doi:10.1124/mol.110.067207.
33. Fox GB, Fan L, Levasseur RA, Faden AI. Sustained sensory/motor and cognitive deficits with neuronal apoptosis following controlled cortical impact brain injury in the mouse. J Neurotrauma 1998;15:599–614.
34. Zhao Z, Loane DJ, Murray MG 2nd, Stoica BA, Faden AI. Comparing the predictive value of multiple cognitive, affective, and motor tasks after rodent traumatic brain injury. J Neurotrauma 2012;29:2475–2489. doi:10.1089/neu.2012.2511.
35. Kumar A, Stoica BA, Sabirzhanov B, Burns MP, Faden AI, Loane DJ. Traumatic brain injury in aged animals increases lesion size and chronically alters microglial/macrophage classical and alternative activation states. Neurobiol Aging 2013;34:1397–1411. doi:10.1016/j.neurobiolaging.2012.11.013.
36. Loane DJ, Pocivavsek A, Moussa CE, et al. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nature Med 2009;15:377–379. doi:10.1038/nm.1940.
37. Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009;4:399–418. doi:10.1007/s11481-009-9164-4.
38. Lynch MA. The multifaceted profile of activated microglia. Mol Neurobiol 2009;40:139–156. doi:10.1007/s12035-009-8077-9.
39. de Paulis T, Hemstapat K, Chen Y, et al. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem 2006;49:3332–3344. doi:10.1021/jm051252j.
40. Noetzel MJ, Rook JM, Vinson PN, et al. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 2012;81:120–133. doi:10.1124/mol.111.075184.
41. Lull ME, Block ML. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010;7:354–365.
42. Piers TM, Heales SJ, Pocock JM. Positive allosteric modulation of metabotropic glutamate receptor 5 down-regulates fibrinogen-activated microglia providing neuronal protection. Neurosci Lett 2011;505:140–145. doi:10.1016/j.neulet.2011.10.007.
43. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35. doi:10.1038/nri978nri978.
44. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677–686.
45. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006;3:27. doi:10.1186/1742-2094-3-27.
46. Ponomarev ED, Maresz K, Tan Y, Dittel BN. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 2007;27:10714–10721. doi:10.1523/JNEUROSCI.1922-07.2007.